Emphysema Market Outlook 2026–2035: Growth Drivers and Industry Forecast

Uncover key drivers, emerging technologies, and competitive movements shaping the emphysema market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Emphysema Market expected to reach by 2030?

The emphysema market size has demonstrated consistent growth over recent years. It is forecast to expand from $4.94 billion in 2025 to $5.17 billion in 2026, at a compound annual growth rate (CAGR) of 4.6%. The expansion observed in the historical period stems from influences such as smoking prevalence, exposure to air pollution, an aging population, increased awareness of respiratory diseases, and the widening access to healthcare.

The emphysema market is projected to experience consistent expansion over the upcoming years. Its value is anticipated to reach $6.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.6%. This projected increase throughout the forecast period stems from factors such as early screening efforts, the rise of home-based respiratory support, the uptake of sophisticated diagnostics, a sharpened focus on managing chronic diseases, and stricter environmental health regulations. Significant developments anticipated during this timeframe involve the growing occurrence of chronic respiratory conditions, a heightened emphasis on the prompt diagnosis of COPD, the proliferation of long-term oxygen therapy, the extension of pulmonary rehabilitation services, and stronger advocacy for smoking cessation strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp

What Drivers Are Driving Adoption Within The Emphysema Market?

The rising incidence of respiratory infections is anticipated to stimulate the expansion of the emphysema market in the future. Respiratory infections are defined as ailments affecting the respiratory system, including areas such as the sinuses, throat, airways, and lungs. The increase in these infections is attributed to factors like pollution, climate change, antimicrobial resistance, urbanization, and evolving pathogens. Respiratory infections hasten the progression of emphysema by inducing inflammation, causing tissue damage, and increasing airway obstruction, which consequently worsens lung function. For instance, in November 2024, data from the Centers for Disease Control and Prevention, a US-based government agency, showed that in 2023, the U.S. reported 9,633 tuberculosis (TB) cases. This marked a 15.6% rise from 8,332 cases in 2022, with the incidence rate increasing by 15.0% from 2.5 to 2.9 per 100,000 persons. Thus, the escalating prevalence of respiratory infections is a significant force driving the growth of the emphysema market.

How Is The Emphysema Market Organized Into Various Segments?

The emphysema market covered in this report is segmented –

1) By Type: Centrilobular, Panlobular

2) By Treatment: Medication, Therapy, Surgery, Other Treatments

3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis

4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications

5) By End-User: Hospitals And Clinics, Surgical Center, Other End-Users

Subsegments:

1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema

2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema

How Are New Market Trends Shaping The Landscape Of The Emphysema Market?

Leading companies active in the emphysema market are prioritizing medical advancements, particularly inhaled dual inhibitors of phosphodiesterase 3 and phosphodiesterase 4, to provide patients with advanced therapies designed to enhance lung function, reduce inflammation, and improve overall disease management, thereby fostering superior respiratory health and quality of life. An inhaled dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4 is a medication engineered to target and block both phosphodiesterase enzymes in the lungs, which assists in relaxing airways and diminishing inflammation, ultimately improving respiration in conditions like chronic obstructive pulmonary disease. As an illustration, in June 2024, Verona Pharma plc, a UK-based pharma company, introduced Ohtuvayre (ensifentrine), which stands as the first inhaled dual PDE3 and PDE4 inhibitor approved by the Food and Drug Administration, a US-based federal agency. This approval is for the maintenance treatment of chronic obstructive pulmonary diseases such as emphysema, representing the first novel inhaled therapy in over 20 years. The drug, which combines bronchodilator and anti-inflammatory effects, will be made available through specialty pharmacies.

Who Are The Top-Performing Companies In The Emphysema Market In Recent Years?

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann-La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, InMed Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Emphysema Market?

North America was the largest region in the emphysema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Emphysema Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp

Browse Through More Reports Similar to the Global Emphysema Market 2026, By The Business Research Company

Pulmonary Embolism Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Anaphylaxis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

Interstitial Lung Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795